← board
ETON
distress 0/10 · well-funded / low risk$43.410%today0% from 52w high
Lead: Wilson disease
Revenue
$24M
Liquidity
$20M
Runway
—
Shares 1y
+2%
Price & events
+184.3% over 6M
CatalystRating changeDilutionFinancingdashed = today
-0.4%
1D
+16.7%
1W
+29.6%
1M
+89.0%
3M
+189.6%
6M
+183.9%
1Y
+1122.7%
2Y
+676.5%
5Y
+435.2%
All
Overview
- Market Cap
- $1.19B
- Enterprise Value
- $1.19B
- Volume
- 34.70K
- 52 Week Range
- $13.89 – $43.58
- Total Shares
- 27.39M
- Float Shares
- 21.05M
- Short %
- 7.44%
- % Held by Insiders
- 4.49%
- % Held by Institutions
- 66.08%
- RVOL
- 0.08x
- Beta
- 0.86
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 5
- 2026-08-06Estimated 45%earningsEarningsEarnings releaseyahoo
- pilot study underwaytrial initiationsecondaryET-700 · pilot study for ET-700 extended-release zinc acetate vs Galzin and placeboSEC 8-K
- February 25, 2026PDUFAPDUFAET-600 · PDUFA target action date for ET-600 NDASEC 8-K
- 2026-02-02partnershipultra-rare disease product candidate · Licensed U.S. marketing rights to an ultra-rare disease product candidateSEC 8-K
- 2025-03-31partnershipIncrelex · Eton out-licensed commercial rights to Increlex outside U.S. to Esteve Pharmaceuticals for €4M upfront and potential €6M option.SEC 8-K
Approved drugs (5)
- DESMODADESMOPRESSIN ACETATE2026 · Prescription
- KHINDIVIHYDROCORTISONE2025 · Prescription
- ALKINDI SPRINKLEHYDROCORTISONE2020 · Prescription
- HEMANGEOLPROPRANOLOL HYDROCHLORIDE2014 · Prescription
- GALZINZINC ACETATE1997 · Prescription
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $49 (+13% upside) · 4 analysts
- 2026-07-17Canaccord GenuityBuy
- 2026-05-15HC Wainwright & Co.Buy
- 2026-03-20B. Riley SecuritiesBuy
- 2026-03-20Craig-HallumBuy
- 2026-03-20HC Wainwright & Co.Buy
- 2026-03-03Craig-HallumBuy
Competitors — Wilson disease
Recent news
- 2026-07-22Eton Pharmaceuticals Inc. (ETON) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
- 2026-07-22Eton Pharmaceuticals: Here Is How I Handle My Position With The Stock Skyrocketing (Downgrade) - Seeking Alpha
- 2026-07-21Eton Pharmaceuticals Inc (ETON) Shares Fall 3.1% -- What GF Scor - GuruFocus
- 2026-07-21Eton Pharmaceuticals Inc (ETON) Shares Fall 3.1% -- What GF Scor - GuruFocus
- 2026-07-20Eton Pharmaceuticals (ETON) Moves 13.8% Higher: Will This Strength Last? - Yahoo Finance
- 2026-07-18ETON Surges As Canaccord Sets Aggressive $60 Price Target - StocksToTrade
- 2026-07-18ETON Jumps As Canaccord’s $60 Price Target Signals Growth - timothysykes.com
- 2026-07-17Opaleye management sells $1.06m in Eton Pharmaceuticals stock - Investing.com
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.